CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...